MA50561A - Composés inhibiteurs de btk - Google Patents

Composés inhibiteurs de btk

Info

Publication number
MA50561A
MA50561A MA050561A MA50561A MA50561A MA 50561 A MA50561 A MA 50561A MA 050561 A MA050561 A MA 050561A MA 50561 A MA50561 A MA 50561A MA 50561 A MA50561 A MA 50561A
Authority
MA
Morocco
Prior art keywords
btk inhibitor
inhibitor compounds
compounds
btk
inhibitor
Prior art date
Application number
MA050561A
Other languages
English (en)
Other versions
MA50561B1 (fr
Inventor
Kenneth James Henry Jr
Albert Khilevich
Steven Lee Kuklish
Katherine Marie Partridge
Steven James Quimby
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA50561A publication Critical patent/MA50561A/fr
Publication of MA50561B1 publication Critical patent/MA50561B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA50561A 2017-11-06 2018-10-30 Composés inhibiteurs de btk MA50561B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762581967P 2017-11-06 2017-11-06
PCT/US2018/058104 WO2019089512A1 (fr) 2017-11-06 2018-10-30 Composés inhibiteurs de btk

Publications (2)

Publication Number Publication Date
MA50561A true MA50561A (fr) 2020-09-16
MA50561B1 MA50561B1 (fr) 2022-03-31

Family

ID=64277913

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50561A MA50561B1 (fr) 2017-11-06 2018-10-30 Composés inhibiteurs de btk

Country Status (34)

Country Link
US (1) US11542249B2 (fr)
EP (1) EP3707133B1 (fr)
JP (1) JP6920553B2 (fr)
KR (1) KR102410202B1 (fr)
CN (1) CN111278818B (fr)
AR (1) AR113796A1 (fr)
AU (1) AU2018360478B2 (fr)
BR (1) BR112020006749A2 (fr)
CA (1) CA3080123C (fr)
CL (1) CL2020001089A1 (fr)
CR (1) CR20200183A (fr)
CY (1) CY1124994T1 (fr)
DK (1) DK3707133T3 (fr)
DO (1) DOP2020000103A (fr)
EA (1) EA039398B1 (fr)
EC (1) ECSP20024395A (fr)
ES (1) ES2904843T3 (fr)
HR (1) HRP20220178T1 (fr)
HU (1) HUE057987T2 (fr)
IL (1) IL273778B (fr)
JO (1) JOP20200104A1 (fr)
LT (1) LT3707133T (fr)
MA (1) MA50561B1 (fr)
MD (1) MD3707133T2 (fr)
MX (1) MX2020004435A (fr)
PE (1) PE20201168A1 (fr)
PL (1) PL3707133T3 (fr)
PT (1) PT3707133T (fr)
RS (1) RS62805B1 (fr)
SG (1) SG11202003178PA (fr)
SI (1) SI3707133T1 (fr)
TW (1) TWI694995B (fr)
UA (1) UA126079C2 (fr)
WO (1) WO2019089512A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021023110A2 (pt) * 2019-05-23 2022-04-12 Novartis Ag Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2499017T3 (es) * 2007-10-23 2014-09-26 F. Hoffmann-La Roche Ag Nuevos inhibidores de quinasa
RU2017112518A (ru) * 2010-05-07 2019-01-25 Джилид Коннектикут, Инк. Пиридоновые и азапиридоновые соединения и способы применения
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
DK2718270T3 (da) * 2011-06-10 2022-08-01 Merck Patent Gmbh Sammensætninger og fremgangsmåder til fremstillingen af pyrimidin- og pyridinforbindelser med btk-hæmmende aktivitet
WO2014093230A2 (fr) * 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions et procédés de fabrication de composés pyrimidine et pyridine ayant une activité inhibitrice de btk
GB2516303A (en) 2013-07-18 2015-01-21 Redx Pharma Ltd Compounds
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
WO2017059280A1 (fr) * 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Nouveaux inhibiteurs de pan-tam et doubles inhibiteurs de mer/axl

Also Published As

Publication number Publication date
HUE057987T2 (hu) 2022-06-28
IL273778B (en) 2022-06-01
US11542249B2 (en) 2023-01-03
HRP20220178T1 (hr) 2022-04-29
WO2019089512A1 (fr) 2019-05-09
EA202090843A1 (ru) 2020-07-24
DOP2020000103A (es) 2020-09-15
MA50561B1 (fr) 2022-03-31
AU2018360478A1 (en) 2020-04-23
BR112020006749A2 (pt) 2020-10-06
CR20200183A (es) 2020-05-30
EP3707133B1 (fr) 2021-12-15
LT3707133T (lt) 2022-01-25
ECSP20024395A (es) 2020-06-30
PE20201168A1 (es) 2020-10-28
CN111278818A (zh) 2020-06-12
CL2020001089A1 (es) 2020-10-23
CY1124994T1 (el) 2023-01-05
CN111278818B (zh) 2023-03-28
JP6920553B2 (ja) 2021-08-18
JP2021501749A (ja) 2021-01-21
NZ764452A (en) 2023-09-29
US20200290997A1 (en) 2020-09-17
KR20200060480A (ko) 2020-05-29
EP3707133A1 (fr) 2020-09-16
PT3707133T (pt) 2022-01-27
IL273778A (en) 2020-05-31
RS62805B1 (sr) 2022-02-28
DK3707133T3 (da) 2022-01-03
TW201930293A (zh) 2019-08-01
SI3707133T1 (sl) 2022-02-28
UA126079C2 (uk) 2022-08-10
CA3080123C (fr) 2021-11-09
TWI694995B (zh) 2020-06-01
PL3707133T3 (pl) 2022-04-04
JOP20200104A1 (ar) 2022-10-30
MX2020004435A (es) 2020-08-06
AU2018360478B2 (en) 2020-09-17
SG11202003178PA (en) 2020-05-28
EA039398B1 (ru) 2022-01-24
AR113796A1 (es) 2020-06-10
MD3707133T2 (ro) 2022-07-31
KR102410202B1 (ko) 2022-06-22
ES2904843T3 (es) 2022-04-06
CA3080123A1 (fr) 2019-05-09

Similar Documents

Publication Publication Date Title
MA49701A (fr) Composés immunomodulateurs
MA47131A (fr) Composés benzyl-amide phosphodiamide antiviraux
MA52948A (fr) Composés
DK3692040T3 (da) Kemiske forbindelser
MA42293A (fr) Composés antibactériens
DK3728252T3 (da) 4-azaindolforbindelser
MA51669A (fr) Composés
MA46242A (fr) Composés inhibiteurs de bêta-lactamase
MA41614A (fr) Composés antiviraux
MA53003A (fr) Composés
DK3298027T3 (da) Anthelmintiske depsipeptidforbindelser
DK4039675T3 (da) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
MA44020A (fr) Composés antitumoraux
MA50504A (fr) Composés antibactériens
MA49623A (fr) Composés chimiques
MA49621A (fr) Composés bifonctionnels
DK3597189T3 (da) Krystallinske forbindelser
MA49522A (fr) Nouveaux composés de quinoléinone
MA42034A (fr) Composés pipéridiniques tricycliques
MA52946A (fr) Composés
MA51221A (fr) Composés de pyrazolopyridinone
DK3374357T3 (da) Disubstituerede diaryloxybenzoheterodiazol-forbindelser
DK3672941T3 (da) Pyridylpyridonforbindelser
MA49880A (fr) Composés anticancéreux
MA49885A (fr) Composés macrocycliques